Lazard Asset Management
GTHX

Lazard Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Lazard Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-298
Closed -$1K – 2470
2024
Q1 		$1K Buy
+298
New +$1.04K ﹤0.01% 2012
2023
Q1 		– Sell
-10,012
Closed -$54K – 2605
2022
Q4 		$54K Buy
+10,012
New +$83.9K ﹤0.01% 1780

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lazard Asset Management's GTHX Position: Q2 2024 in Review

Lazard Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 298 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in GTHX in Q4 2022 and held it in 2 quarters. The position peaked at $54K in Q4 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Lazard Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Lazard Asset Management sold 298 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1K.
  • Lazard Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Lazard Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $54K in Q4 2022.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.